BAJAJ BROKING

Notification close image
No new Notification messages
card image
🚨 TRADING HOLIDAY 🚨
The NSE and BSE will remain closed for trading and settlement on Wednesday, August 27, 2025, on account of Ganesh Chaturthi.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

19265

506197

BLISSGVS

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Bliss Gvs Pharma performance

Today’s low

Today’s high

₹ 157.22 ₹ 164.20
₹ 163.13

52 week low

52 week high

₹ 106.04 ₹ 190.97
₹ 163.13

Open Price

₹ 158.23

Prev. Close

₹ 159.02

Volume (Shares)

532906.00

Total traded value

₹ 869.32

Upper Circuit

₹ 190.82

Lower Circuit

₹ 127.21

info

Bliss Gvs Pharma Share Price Update

As of the latest trading session, Bliss Gvs Pharma share price is currently at ₹ 162.8, which is up by ₹ 3.77 from its previous closing. Today, the stock has fluctuated between ₹ 157.22 and ₹ 164.20. Over the past year, Bliss Gvs Pharma has achieved a return of 21.65 %. In the last month alone, the return has been 3.52 %. Read More...

Investment Returns

Over 1 Month 3.52% Over 3 Months 26.60% Over 6 Months 17.56% Over 1 Year 21.65%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Bliss Gvs Pharma fundamentals


  • Market cap (Cr)

    1,723.50

  • P/E Ratio (TTM)

    23.77

  • Beta

    1.22

  • Book Value / share

    100.34

  • Return on equity

    6.74%

  • EPS (TTM)

    6.69

  • Dividend yield

    0.31%

  • Net profit/quarter (Cr)

    21.05

info icon alternate text
  • Market cap (Cr)

    1,722.80

  • P/E Ratio (TTM)

    23.77

  • Beta

    1.11

  • Book Value / share

    100.34

  • Return on equity

    6.74%

  • EPS (TTM)

    6.69

  • Dividend yield

    0.31%

  • Net profit/quarter (Cr)

    21.05

info icon alternate text

Bliss Gvs Pharma Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 163.36
Operating Expense 143.39
Net Profit 21.05
Net Profit Margin (%) 12.88
Earnings Per Share (EPS) 2.00
EBITDA 43.35
Effective Tax Rate (%) 31.11
Particulars MAR 2025 (Values in Cr)
Revenue 156.00
Operating Expense 151.01
Net Profit 11.45
Net Profit Margin (%) 7.33
Earnings Per Share (EPS) 1.08
EBITDA 23.09
Effective Tax Rate (%) 20.19
Particulars DEC 2024 (Values in Cr)
Revenue 179.59
Operating Expense 161.48
Net Profit 21.05
Net Profit Margin (%) 11.72
Earnings Per Share (EPS) 2.00
EBITDA 37.40
Effective Tax Rate (%) 29.29
Particulars SEP 2024 (Values in Cr)
Revenue 182.65
Operating Expense 167.10
Net Profit 17.04
Net Profit Margin (%) 9.32
Earnings Per Share (EPS) 1.63
EBITDA 33.73
Effective Tax Rate (%) 28.67
Particulars JUN 2024 (Values in Cr)
Revenue 148.96
Operating Expense 129.64
Net Profit 19.42
Net Profit Margin (%) 13.03
Earnings Per Share (EPS) 1.85
EBITDA 33.58
Effective Tax Rate (%) 25.73
Particulars MAR 2025 (Values in Cr)
Revenue 667.20
Operating Expense 609.25
Net Profit 68.97
Net Profit Margin (%) 10.33
Earnings Per Share (EPS) 6.56
EBITDA 127.80
Effective Tax Rate (%) 26.76
Particulars MAR 2024 (Values in Cr)
Revenue 605.46
Operating Expense 527.61
Net Profit 50.64
Net Profit Margin (%) 8.36
Earnings Per Share (EPS) 4.85
EBITDA 99.59
Effective Tax Rate (%) 27.91
Particulars MAR 2023 (Values in Cr)
Revenue 598.34
Operating Expense 533.42
Net Profit 85.48
Net Profit Margin (%) 14.28
Earnings Per Share (EPS) 8.23
EBITDA 140.92
Effective Tax Rate (%) 26.11
Particulars MAR 2022 (Values in Cr)
Revenue 636.36
Operating Expense 545.33
Net Profit 92.66
Net Profit Margin (%) 14.56
Earnings Per Share (EPS) 8.97
EBITDA 144.57
Effective Tax Rate (%) 26.69
Particulars MAR 2021 (Values in Cr)
Revenue 465.51
Operating Expense 392.01
Net Profit 67.50
Net Profit Margin (%) 14.50
Earnings Per Share (EPS) 6.54
EBITDA 109.14
Effective Tax Rate (%) 25.97
Particulars MAR 2025 (Values in Cr)
Book Value / Share 99.68
ROE % 8.95
ROCE % 12.09
Total Debt to Total Equity 0.09
EBITDA Margin 20.15
Particulars MAR 2024 (Values in Cr)
Book Value / Share 92.38
ROE % 11.02
ROCE % 14.84
Total Debt to Total Equity 0.11
EBITDA Margin 23.25
Particulars MAR 2023 (Values in Cr)
Book Value / Share 84.87
ROE % 9.01
ROCE % 12.14
Total Debt to Total Equity 0.12
EBITDA Margin 17.98
Particulars MAR 2022 (Values in Cr)
Book Value / Share 78.97
ROE % 5.35
ROCE % 14.23
Total Debt to Total Equity 0.14
EBITDA Margin 20.04
Particulars MAR 2021 (Values in Cr)
Book Value / Share 78.36
ROE % 9.58
ROCE % 12.20
Total Debt to Total Equity 0.16
EBITDA Margin 21.98
Particulars MAR 2025 (Values in Cr)
Book Value / Share 100.47
ROE % 6.74
ROCE % 9.16
Total Debt to Total Equity 0.07
EBITDA Margin 19.15
Particulars MAR 2024 (Values in Cr)
Book Value / Share 94.41
ROE % 7.91
ROCE % 11.18
Total Debt to Total Equity 0.08
EBITDA Margin 23.18
Particulars MAR 2023 (Values in Cr)
Book Value / Share 89.96
ROE % 9.56
ROCE % 12.81
Total Debt to Total Equity 0.10
EBITDA Margin 23.55
Particulars MAR 2022 (Values in Cr)
Book Value / Share 82.12
ROE % 11.53
ROCE % 14.59
Total Debt to Total Equity 0.11
EBITDA Margin 22.72
Particulars MAR 2021 (Values in Cr)
Book Value / Share 73.26
ROE % 9.38
ROCE % 11.71
Total Debt to Total Equity 0.13
EBITDA Margin 23.45
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 213.30
Total Assets 1300.83
Total Liabilities 1300.83
Total Equity 1091.84
Share Outstanding 105370272
Price to Book Ratio 1.17
Return on Assets (%) 6.48
Return on Capital (%) 7.25
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 215.61
Total Assets 1211.58
Total Liabilities 1211.58
Total Equity 1002.98
Share Outstanding 104690822
Price to Book Ratio 1.19
Return on Assets (%) 6.22
Return on Capital (%) 6.92
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 102.98
Total Assets 1156.85
Total Liabilities 1156.85
Total Equity 917.42
Share Outstanding 104152672
Price to Book Ratio 0.79
Return on Assets (%) 6.12
Return on Capital (%) 6.98
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 177.52
Total Assets 1108.74
Total Liabilities 1108.74
Total Equity 846.46
Share Outstanding 103677922
Price to Book Ratio 0.94
Return on Assets (%) 1.35
Return on Capital (%) 1.58
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 144.55
Total Assets 1076.78
Total Liabilities 1076.78
Total Equity 827.90
Share Outstanding 103146672
Price to Book Ratio 1.35
Return on Assets (%) 6.36
Return on Capital (%) 7.23
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 171.10
Total Assets 1219.69
Total Liabilities 1219.69
Total Equity 1058.63
Share Outstanding 105370272
Price to Book Ratio 1.17
Return on Assets (%) 5.65
Return on Capital (%) 6.22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 169.31
Total Assets 1150.27
Total Liabilities 1150.27
Total Equity 988.44
Share Outstanding 104690822
Price to Book Ratio 1.19
Return on Assets (%) 4.40
Return on Capital (%) 4.8
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 84.60
Total Assets 1139.69
Total Liabilities 1139.69
Total Equity 936.99
Share Outstanding 104152672
Price to Book Ratio 0.79
Return on Assets (%) 7.50
Return on Capital (%) 8.43
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 149.48
Total Assets 1079.96
Total Liabilities 1079.96
Total Equity 851.43
Share Outstanding 103677922
Price to Book Ratio 0.94
Return on Assets (%) 8.58
Return on Capital (%) 9.89
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 119.51
Total Assets 945.62
Total Liabilities 945.62
Total Equity 755.64
Share Outstanding 103146672
Price to Book Ratio 1.35
Return on Assets (%) 7.13
Return on Capital (%) 7.99
Particulars MAR 2025 (Values in Cr)
Net Income 125.63
Cash from Operations 142.54
Cash from Investing -75.44
Cash from Financing -30.34
Net change in Cash 0.12
Free Cash Flow 218.61
Particulars MAR 2024 (Values in Cr)
Net Income 146.06
Cash from Operations 137.66
Cash from Investing -83.18
Cash from Financing -20.89
Net change in Cash -1.26
Free Cash Flow 165.99
Particulars MAR 2023 (Values in Cr)
Net Income 106.07
Cash from Operations 78.86
Cash from Investing -7.75
Cash from Financing -24.93
Net change in Cash 1.62
Free Cash Flow 172.66
Particulars MAR 2022 (Values in Cr)
Net Income 127.75
Cash from Operations 169.42
Cash from Investing -92.97
Cash from Financing -23.73
Net change in Cash 18.77
Free Cash Flow 243.42
Particulars MAR 2021 (Values in Cr)
Net Income 104.12
Cash from Operations 92.53
Cash from Investing -46.99
Cash from Financing -20.79
Net change in Cash -3.81
Free Cash Flow 101.65
Particulars MAR 2025 (Values in Cr)
Net Income 94.17
Cash from Operations 127.53
Cash from Investing -77.72
Cash from Financing -26.70
Net change in Cash -7.22
Free Cash Flow 196.03
Particulars MAR 2024 (Values in Cr)
Net Income 111.34
Cash from Operations 111.51
Cash from Investing -65.83
Cash from Financing -20.75
Net change in Cash -4.42
Free Cash Flow 150.18
Particulars MAR 2023 (Values in Cr)
Net Income 115.69
Cash from Operations 81.52
Cash from Investing -12.97
Cash from Financing -26.04
Net change in Cash 4.78
Free Cash Flow 175.81
Particulars MAR 2022 (Values in Cr)
Net Income 123.65
Cash from Operations 144.51
Cash from Investing -92.28
Cash from Financing -12.62
Net change in Cash 9.14
Free Cash Flow 218.18
Particulars MAR 2021 (Values in Cr)
Net Income 91.18
Cash from Operations 89.68
Cash from Investing -61.62
Cash from Financing -11.67
Net change in Cash -6.32
Free Cash Flow 97.74
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.30 13.59 1.82 255.19 30.00 / 69.75
CIPLA LTD 1601.10 23.98 4.14 129329.50 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 323.75 9.12 2.62 952.83 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2799.20 50.08 24.30 47420.14 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.30 18.10 5.26 255.19 30.00 / 69.75
AMRUTAJAN HEALTH LTD 708.10 37.55 6.26 2047.16 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8297.10 98.09 26.92 20742.75 6222.35 / 10653.05
ABBOTT INDIA LIMITED 31527.60 46.13 15.82 66996.15 25260.20 / 35921.55

Bliss Gvs Pharma Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
163.37 2.73 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 163.80
  • 26 Days 166.20
  • 10 Days 166.90
  • 50 Days 159.90
  • 12 Days 167.40
  • 100 Days 150.90
  • 20 Days 167.30
  • 200 Days 142.80
160.29 PIVOT

First Support

156.94

First Resistance

162.37

Second Support

154.86

Second Resistance

165.72

Third Support

151.51

Third Resistance

167.80

RSI

42.44

ADX

56.15

MACD

1.21

Williams % R

-97.28

Commodity Channel Index (CCI)

-127.32

Date

2025-08-25

Week

391496.00

Same Day

263629.00

Month

421840.00

1 Year

1.23

3 Year

0.91

Over 1 Month

3.52%

down

Over 1 Year

21.65%

down

Over 3 Months

26.60%

down

Over 3 Years

26.85%

down

Over 6 Months

17.56%

down

Over 5 Years

0.26%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Bliss Gvs Pharma shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
45.36%
Promoter Holdings
35.43%
FII
12.65%
DII
6.54%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Narsimha Shibroor Kamath 3.2437024E7 (30.75%) Shareholding of Promoter and Promoter Group
Arian Investment Limited 8368908.0 (7.93%) Public Shareholding
Life Insurance Corporation Of India 6901355.0 (6.54%) Public Shareholding
Gulbarga Trading And Investment Private 5832000.0 (5.53%) Public Shareholding
Arjun Gautam Ashra . 5049000.0 (4.79%) Public Shareholding
Gautam Rasiklal Ashra 2981571.0 (2.83%) Public Shareholding
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 2569517.0 (2.44%) Public Shareholding
Vibha Gagan Sharma 2575000.0 (2.44%) Shareholding of Promoter and Promoter Group
Shruti Vishal Rao 2110000.0 (2.0%) Shareholding of Promoter and Promoter Group
Coeus Global Opportunities Fund 1859594.0 (1.76%) Public Shareholding
Gagan Harsh Sharma 200000.0 (0.19%) Shareholding of Promoter and Promoter Group
Ramadas Vasudev Kamath Huf 28988.0 (0.03%) Shareholding of Promoter and Promoter Group
Punita Sharma 24962.0 (0.02%) Shareholding of Promoter and Promoter Group
Shibroor Gokuldas Kamath 8000.0 (0.01%) Shareholding of Promoter and Promoter Group
Keetup India Private Limited 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Aayushi Realtors Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Gnr Enterprises 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Gvsk Llp 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vinita Siddhesh Shenoy 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Lalita Bhatia 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Madhuri Naygandhi 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Rajendra Bhatia 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Jagdishchandra Dhutia 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Radha Nayak 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Meera Vijay Rao 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vijay Bhavanishanker Rao 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Lalneet Sharma 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shagun Sharma 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Radha Sharma 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shiv Kumar Sharma 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Vishal Vijay Rao 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Shibroor Ravidas Kamath 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Geeta Narsimha Kamath 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Ramadas Vasudev Kamath. 3200.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Bliss Gvs Pharma corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
24 Jul 2025 0.5 Final 24 Jul 2025 Equity shares
18 Jul 2024 0.5 Final 19 Jul 2024 Equity shares
12 Jul 2023 0.5 Final 13 Jul 2023 Equity shares
20 Jun 2022 0.5 Final 21 Jun 2022 Equity shares
13 Sep 2021 0.5 Final 14 Sep 2021 Equity shares
17 Sep 2020 0.5 Final 19 Sep 2020 Equity shares
12 Sep 2019 1.0 Final 14 Sep 2019 Equity shares
14 Aug 2018 1.0 Final 18 Aug 2018 Equity shares
18 Sep 2017 0.6 Final 20 Sep 2017 Equity shares
06 Sep 2016 0.5 Final 08 Sep 2016 Equity shares
08 Sep 2015 0.5 Final 10 Sep 2015 Equity shares
24 Feb 2015 0.2 Interim 25 Feb 2015 Equity shares
13 Aug 2014 0.5 Final 18 Aug 2014 Equity shares
01 Aug 2013 0.4 Final 05 Aug 2013 Equity shares
25 Feb 2013 0.3 Interim 26 Feb 2013 Equity shares
02 Aug 2012 0.4 Final 06 Aug 2012 Equity shares
24 Nov 2011 0.35 Interim 25 Nov 2011 Equity shares
14 Jul 2011 0.3 Final 18 Jul 2011 Equity shares
25 Nov 2010 0.3 Interim 27 Nov 2010 Equity shares
22 Jul 2010 0.5 Final 26 Jul 2010 Equity shares
13 Aug 2009 0.15 Final 17 Aug 2009 Equity shares
14 May 2008 0.1 Interim 15 May 2008 Equity shares
13 Sep 2007 1.0 Final 17 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
30 Sep 2008 26 Sep 2008 3:5
01 Oct 2005 28 Sep 2005 2:5
Ex-Date Old FV NEW FV Record Date
11 Mar 2008 10.0 1.0 18 Mar 2008
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
24 Jul 2025 0.5 Final 24 Jul 2025 Equity shares
18 Jul 2024 0.5 Final 19 Jul 2024 Equity shares
12 Jul 2023 0.5 Final 13 Jul 2023 Equity shares
20 Jun 2022 0.5 Final 21 Jun 2022 Equity shares
13 Sep 2021 0.5 Final 14 Sep 2021 Equity shares
17 Sep 2020 0.5 Final 19 Sep 2020 Equity shares
12 Sep 2019 1.0 Final 14 Sep 2019 Equity shares
14 Aug 2018 1.0 Final 18 Aug 2018 Equity shares
18 Sep 2017 0.6 Final 20 Sep 2017 Equity shares
06 Sep 2016 0.5 Final 08 Sep 2016 Equity shares
08 Sep 2015 0.5 Final 10 Sep 2015 Equity shares
24 Feb 2015 0.2 Interim 25 Feb 2015 Equity shares
13 Aug 2014 0.5 Final 18 Aug 2014 Equity shares
01 Aug 2013 0.4 Final 05 Aug 2013 Equity shares
25 Feb 2013 0.3 Interim 26 Feb 2013 Equity shares
02 Aug 2012 0.4 Final 06 Aug 2012 Equity shares
24 Nov 2011 0.35 Interim 25 Nov 2011 Equity shares
14 Jul 2011 0.3 Final 18 Jul 2011 Equity shares
25 Nov 2010 0.3 Interim 27 Nov 2010 Equity shares
22 Jul 2010 0.5 Final 26 Jul 2010 Equity shares
13 Aug 2009 0.15 Final 17 Aug 2009 Equity shares
14 May 2008 0.1 Interim 15 May 2008 Equity shares
13 Sep 2007 1.0 Final 17 Sep 2007 Equity shares
Ex-Date Ex-Bonus Ratio
30 Sep 2008 26 Sep 2008 3:5
01 Oct 2005 28 Sep 2005 2:5
Ex-Date Old FV NEW FV Record Date
11 Mar 2008 10.0 1.0 18 Mar 2008

Bliss Gvs Pharma Share Price

Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984. The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006.

The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its manufacturing facility at Palghar which is WHO GMP approved. The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards.

The company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharma's R&D center, received approval from Government of India's Department for Scientific & Industrial Research (DSIR).

During the year under review, the company invested in 51% share capital of Lifeon Labs Pvt Ltd.

During the year under review, Bliss GVS Pharma faced challenges in Ghana, where delays in registration resulted in adverse regulatory action. However, the company took quick, corrective measures to resolve these issues. The business is now backing on track in Ghana.

During the year ended 31 March 2015, Bliss GVS Pharma formed a new company Asterisk Lifesciences Limited as a wholly owned foreign subsidiary in United Kingdom for the purpose of facilitating registrations and marketing of pharmaceutical formulations in the European continent.

During the financial year ended 31 March 2016, Bliss GVS Pharma continued to grow in various geographies in Kenya, Nigeria and France. Such growth was mainly achieved due to contract manufacturing and consistent focus on new product launch in Kenya and Nigeria.

Bliss GVS Pharma continued to strengthen its operations and creation of robust Quality Manufacturing operations during the year ended 31 March 2017,

The company's investment in managed healthcare services delivered encouraging results with the company procuring USD 111.40 mMillion contract from Aon.

During the year ended 31 March 2018, Bliss GVS Pharma divested three subsidiaries viz. Lifeon Labs Private Limited, Bliss Indasi Lifescience Private Limited and Shree Salespack Private Limited and one materially significant step down subsidiary Bliss GVS Healthcare Limited, Nairobi to focus on its core pharmaceutical operations, which have been a steady source of growth.

The Company set up a multi-dosage facility at Vevoor, Maharashtra in 2019. The first phase commissioned earlier in March, 2020, primarily for Tablets, Capsules, Dry Syrups, and Sachets. While the second phase commenced construction in January, 2021.

The Company achieved USFDA approval for the manufacturing unit at Palghar in FY 2024. In FY 2025, it commissioned a state-of-the-art semi-solid plant at Vevoor. It singed strategic agreements with clients across the US, Canada and Europe, by adding presence in regulated market during the year 2025.

Parent organization Indian Private
NSE symbol BLISSGVS
Founded 1984
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Bliss GVS Pharma Ltd?

Answer Field

Bliss GVS Pharma Ltd share price is for NSE ₹ 162.80 & for BSE ₹ 162.85 as on Aug 26 2025 03:30 PM.

What is the Market Cap of Bliss GVS Pharma Ltd Share?

Answer Field

The market cap of Bliss GVS Pharma Ltd for NSE ₹ 1,715.42 & for BSE ₹ 1,715.95 as on Aug 26 2025 03:30 PM.

What is the 52 Week High and Low of Bliss GVS Pharma Ltd?

Answer Field

The 52 Week High and Low of Bliss GVS Pharma Ltd for NSE is ₹ 190.97 and ₹ 106.04 and for BSE is ₹ 190.65 and ₹ 105.05.

What is 1 year return for Bliss GVS Pharma Ltd?

Answer Field

The 1 year returns on the stock has been 21.65%.

What is the P/E Ratio of Bliss GVS Pharma Ltd Share?

Answer Field

As on Aug 26 2025 03:30 PM the price-to-earnings (PE) ratio for Bliss GVS Pharma Ltd share is 23.77.

What is the PB ratio of Bliss GVS Pharma Ltd Share?

Answer Field

As on Aug 26 2025 03:30 PM, the price-to-book (PB) ratio for Bliss GVS Pharma Ltd share is 100.34.

How to Buy Bliss GVS Pharma Ltd Share?

Answer Field

You can trade in Bliss GVS Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Bliss GVS Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Bliss GVS Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Bliss GVS Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91